Dr. Ai-ris Y. Collier, M.D.
Maternal-Fetal Medicine (High-Risk Pregnancy) (Maternal & Fetal Medicine Physician)
At a glance
- Medical school
- Harvard Medical School (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Harvard Medical School
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Maternal & Fetal Medicine Physician primary
MA license 263264 -
Obstetrics Physician
MA license 263264
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Maternal-Fetal Medicine (High-Risk Pregnancy) per capita by county →
Where they work
Hospitals
- Beth Israel Deaconess Medical Center Boston, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $23,915 in research payments for these studies, mostly to the institutions running them.
- Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
Sanofi Pasteur Inc. · Active, not recruiting · NCT04942210 - A phase 1 openlabel study to evaluate the pharmacokinetics safety and tolerability of orally administered nirmatrelvirritonavir in pregnant women with mildtomoderate COVID19
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.